- This topic is empty.
-
Posts
-
Recently, the infliximab biosimilar (Trade Name: Reminton®), developed by Mabpharm and licensed to Kexing Biopharm, has received marketing approval from the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. To date, Reminton® has successfully gained market access in several countries including Peru, Bangladesh, and Pakistan, marking rapid progress in its internationalization.
Infliximab for Injection (Reminton®) was approved for market in China by the National Medical Products Administration (NMPA) in July 2021 (Approval Number: Guo Yao Zhun Zi S20210025). It is the first infliximab biosimilar approved for marketing in China, indicated for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult and pediatric (6 years and older) Crohn's disease, fistulizing Crohn's disease, and adult ulcerative colitis.
According to data from Frost & Sullivan, the global autoimmune disease drug market grew from USD 116.9 billion in 2019 to USD 138.9 billion in 2024, representing a compound annual growth rate (CAGR) of 3.5%. It is projected to reach USD 176.7 billion by 2030. In 2024, biologics accounted for approximately 76.5% of the global autoimmune disease drug market. In the Chinese infliximab market, Reminton® held a 10.6% share in 2024, ranking second.
In recent years, Kexing Biopharm has focused on areas such as oncology and autoimmune diseases, establishing overseas commercialization partnerships for multiple products with several renowned domestic pharmaceutical companies. These efforts not only facilitate the entry of high-quality Chinese-made drugs into global markets but also continuously inject new momentum into the company's global development.
https://www.kexingbiopharm.com/
Kexing Biopharm
- You must be logged in to reply to this topic.